×




Plavix: Drugs in the Age of Personalized Medicine Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for Plavix: Drugs in the Age of Personalized Medicine case study


At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. Plavix: Drugs in the Age of Personalized Medicine case study is a Harvard Business School (HBR) case study written by Richard G. Hamermesh, Mara G. Aspinall, Rachel Gordon. The Plavix: Drugs in the Age of Personalized Medicine (referred as “Plavix Plavix's” from here on) case study provides evaluation & decision scenario in field of Innovation & Entrepreneurship. It also touches upon business topics such as - Value proposition, Marketing.

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment






Case Description of Plavix: Drugs in the Age of Personalized Medicine Case Study


PIavix, one of the world's best selling drugs in 2010, appears to have a limited future. Its patent was due to expire soon and recently new data had been discovered which indicated that a small subset of the population would be at risk for stroke, heart attack or even death if they took PIavix. As a result the FDA had added a black box warning-the agency's most severe--to Plavix's label in 2010. In addition, it had been discovered that the common combination of Plavix and Prilosec, an over-the-counter drug, could adversely affect patients. Finally, Plavix faced new competition from two new drugs with different mechanisms of action. This case reviews the recent history of Plavix in greater detail to encourage a discussion of the following questions: How might the current manufacturers of Plavix handle these emerging threats to their leading blockbuster? How might Plavix's potential competitors utilize Plavix's mixed history to their advantage? How should genotyping be integrated into the clinical care of patients in the light of emerging knowledge?


Case Authors : Richard G. Hamermesh, Mara G. Aspinall, Rachel Gordon

Topic : Innovation & Entrepreneurship

Related Areas : Marketing




Calculating Net Present Value (NPV) at 6% for Plavix: Drugs in the Age of Personalized Medicine Case Study


Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 6 %
Discounted
Cash Flows
Year 0 (10018529) -10018529 - -
Year 1 3457871 -6560658 3457871 0.9434 3262142
Year 2 3978854 -2581804 7436725 0.89 3541166
Year 3 3963632 1381828 11400357 0.8396 3327942
Year 4 3232079 4613907 14632436 0.7921 2560109
TOTAL 14632436 12691360




The Net Present Value at 6% discount rate is 2672831

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting


What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.




Capital Budgeting Approaches

Methods of Capital Budgeting


There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Profitability Index
2. Payback Period
3. Internal Rate of Return
4. Net Present Value

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Timing of the expected cash flows – stockholders of Plavix Plavix's have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.
2. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Plavix Plavix's shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.






Formula and Steps to Calculate Net Present Value (NPV) of Plavix: Drugs in the Age of Personalized Medicine

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Innovation & Entrepreneurship Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Plavix Plavix's often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Plavix Plavix's needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.



Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 15 %
Discounted
Cash Flows
Year 0 (10018529) -10018529 - -
Year 1 3457871 -6560658 3457871 0.8696 3006844
Year 2 3978854 -2581804 7436725 0.7561 3008585
Year 3 3963632 1381828 11400357 0.6575 2606152
Year 4 3232079 4613907 14632436 0.5718 1847952
TOTAL 10469534


The Net NPV after 4 years is 451005

(10469534 - 10018529 )








Calculating Net Present Value (NPV) at 20%


If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 20 %
Discounted
Cash Flows
Year 0 (10018529) -10018529 - -
Year 1 3457871 -6560658 3457871 0.8333 2881559
Year 2 3978854 -2581804 7436725 0.6944 2763093
Year 3 3963632 1381828 11400357 0.5787 2293769
Year 4 3232079 4613907 14632436 0.4823 1558680
TOTAL 9497101


The Net NPV after 4 years is -521428

At 20% discount rate the NPV is negative (9497101 - 10018529 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Plavix Plavix's to discount cash flow at lower discount rates such as 15%.





Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Plavix Plavix's has a NPV value higher than Zero then finance managers at Plavix Plavix's can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Plavix Plavix's, then the stock price of the Plavix Plavix's should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Plavix Plavix's should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

Understanding of risks involved in the project.

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

What can impact the cash flow of the project.

What will be a multi year spillover effect of various taxation regulations.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.






Negotiation Strategy of Plavix: Drugs in the Age of Personalized Medicine

References & Further Readings

Richard G. Hamermesh, Mara G. Aspinall, Rachel Gordon (2018), "Plavix: Drugs in the Age of Personalized Medicine Harvard Business Review Case Study. Published by HBR Publications.


Yan Tat SWOT Analysis / TOWS Matrix

Technology , Semiconductors


Galileo Tech SWOT Analysis / TOWS Matrix

Services , Business Services


GP Global Power SWOT Analysis / TOWS Matrix

Capital Goods , Construction Services


Generation Pass SWOT Analysis / TOWS Matrix

Technology , Computer Services


Crexendo SWOT Analysis / TOWS Matrix

Technology , Computer Services


Imasen Electric Industrial SWOT Analysis / TOWS Matrix

Consumer Cyclical , Auto & Truck Parts


Elevate Credit SWOT Analysis / TOWS Matrix

Financial , Consumer Financial Services


Fair Isaac SWOT Analysis / TOWS Matrix

Technology , Software & Programming


Labgenomics SWOT Analysis / TOWS Matrix

Healthcare , Healthcare Facilities